Dr. Erlinda Maria Gordon, MD

Expert Publications

• Clinical protocol. Tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic t
• Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.
• First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
• Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype.
• Gene therapy in a murine model for clinical application to multiple sclerosis.
• Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors.
• Nanotechnology blooms, at last (Review).
• Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.
• Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.
• The 'timely' development of Rexin-G: first targeted injectable gene vector (review).
• Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.
• Rexin-G, a targeted genetic medicine for cancer.
• Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent.
• Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery.

Clinical Trials

• Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma
• Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma

Media Releases

Get to know Pediatric Hematologist-Oncologist Dr. Erlinda Maria Gordon, who serves patients in Santa Monica, California.

Dr. Gordon is an experienced pediatric hematologist-oncologist, cancer drug developer, biopharmaceutical founder and executive with a proven track record in translational biomedical research, patient care and cancer drug development. Currently, she serves as the Director of Biological and Immunological Therapies and the Chairman of the NIH-approved Institutional Biosafety Committee at the Sarcoma Oncology Center in Santa Monica, California.

The mission of the Sarcoma Oncology Center is to provide the best possible care for all their cancer patients. They promise to support their patients and offer the best possible care regardless of the gravity of their illness. Meeting their patients’ medical and personal needs is their highest priority. They give clear and comprehensive information to help them make informed decisions and participate in their own medical care. They believe that compassion and mutual respect are essential for success in meeting all the dimensions of cancer care.

A native of the Philippines, Dr. Gordon received her medical degree from the University of Santo Tomas Medical College of Medicine and Surgery in 1971. Upon relocating to the United States, she completed her residency in anatomic & clinical pathology with the MetroHealth System in 1974, and her residency in pediatrics at the same educational venue in 1976. Finally, she completed her fellowship in pediatric hematology/oncology at the Case Western Reserve University in 1978.

A Diplomate of the American Board of Pediatric Hematology/Oncology, she was a Tenured Associate Professor for 24 years and is a Professor Emeritus at the USC Keck School of Medicine in Los Angeles, California. There, she licensed the First Academic Vector Production Unit at the Norris Comprehensive Cancer Center, served as its first Medical Director for eight years, and was the Gene Therapy Sponsor for clinical protocols using Targeted Genetic Medicines for Cancer.

Furthermore, Dr. Gordon is the co-founder of two biotechnology companies and is a pioneer in the development of targeted gene therapy products. In her position as FDA liaison for these companies, she gained FDA orphan drug approval and fast track designation for pancreatic cancer, soft tissue sarcoma and osteosarcoma and accelerated approval for Rexin-G, the world’s first targeted genetic medicine for cancer.

Throughout her illustrious career, she has been the co-inventor of more than 150 patents in biomedical research, and patented the first targeted gene delivery system for cancer in the USA, Europe and the Philippines. She has authored more than 100 original peer-reviewed articles and served as Editor-in-Chief of the International Journal of Pediatric Hematology-Oncology, Director of the Red Cell Defects Program and the NIH-funded Comprehensive Hemophilia Center at Children’s Hospital of Los Angeles and the NIH-funded Children’s Oncology Group.

Pediatric oncology is a medical specialty focused on the care of children with cancer. A pediatric hematologist/oncologist is a physician who has special training and experience to diagnose and treat blood disorders and cancers in children, teens, and young adults.

As a testament to her success, Dr. Gordon has been the recipient of the Los Angeles Award for Excellence in Biotechnology Research, the National Institutes of Health Research Career Development Award and NIH/FDA funded grant awards. She was also a nominee for the prestigious Thomas Award for Excellence in Research in 2016.

Recommended Articles

• The Use of Surgery for Ulcerative Colitis

  Ulcerative colitis (UC) is a chronic, inflammatory bowel disease that causes inflammation in the digestive tract. It is usually only in the innermost lining of the large intestine (colon) and rectum. It ranges from mild to severe. Ulcerative colitis is usually not a very serious condition and as...

• Dating with Genital Warts

  Have you ever felt shy approaching a cute gal or guy across the room just because you have genital warts? Well, if you are suffering from this condition, you might be having the fear of rejection, which keeps you from forming relationships. The stigma of genital warts and resulting insecurities not...

• What Are the Types of Bipolar Disorder?

  What is bipolar disorder?Bipolar disorder is a mental illness characterized by extreme mood swings. The mood swings can be extremely high or low. They can last a few hours, days, weeks or even months. The mood swings consist of mixed emotions both of extreme happiness or extreme depression.Bipolar...

• What is Bladder Cancer: Get the Facts

  What is Bladder Cancer?: Get the FactsBladder cancer is a condition caused by Bladder abnormal tissue/cell growth also known as tumor. As its name suggests, Bladder Cancer occurs as a result of abnormal growth of cells lining the Bladder. The tumor spreads into the adjacent muscles and other cells...

• What Are the Treatment Options for Dandruff?

  Dandruff is one of the most embarrassing skin conditions marked by itching and flaking in the scalp. This skin condition, though difficult to treat, can be controlled to a large extent. Under normal conditions, new skin cells replace the old and worn out cells that then fall off. In some people, the...

• Late Stage Alzheimer's Patients Failing to Get Proper Care

  There are some symptoms and conditions that have been discovered over time that stand out as especially difficult when it comes to how healthcare providers and medical specialist centers can help specific patients.  Such can be the case for ailments that specifically worsen in the terminal phase of...